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Abstract Synergy study with chemotherapeutic agents is
a common in vitro strategy in the search for effective
cancer therapy. For non-chemotherapeutic agents, efﬁca-
cious synergistic effects are uncommon. Here, we have
examined two non-chemotherapeutic agents for synergistic
effects: lovastatin and Tumor Necrosis Factor (TNF)-rela-
ted apoptosis-inducing ligand (TRAIL) for synergistic
effects; on three human malignant glioblastoma cell lines,
M059K, M59J, and A172. Cells treated with lovastatin plus
TRAIL for 48 h showed 50% apoptotic cell death, whereas
TRAIL alone (1,000 ng/ml) did not, suggesting that lova-
statin sensitized the glioblastoma cells to TRAIL attack.
Cell cycle analysis indicated that lovastatin increased G0–
G1 arrest in these cells. Annexin V study demonstrated that
apoptosis was the predominant mode of cell death. We
conclude that the combination of lovastatin and TRAIL
enhances apoptosis synergistically. Moreover, lovastatin
sensitized glioblastoma cells to TRAIL, suggesting a new
strategy to treat glioblastoma.
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Introduction
Glioblastomas are the most common intracranial brain
tumors. Its prognosis is usually poor, with survival times of
less than 15 months from ﬁrst diagnosis [1]. Surgical
resection and chemotherapy are common treatments [2].
Despite recent advances in the understanding of the
molecular mechanism of tumourogenesis, the outcome of
malignant glioma remains poor [3]. Thus, new effective
forms of therapy are needed.
The Tumor Necrosis Factor-Related Apoptosis-Inducing
Ligand (TRAIL) [4], a member of the TNF superfamily,
can bind with death receptors, DR4 and DR5 [5, 6] and
induces apoptosis in a wide range of cancer cells without
harming normal cells. The speciﬁc property of TRAIL has
attracted many researchers to look for new treatments by
combining it with chemotherapeutic agents such as phen-
oxazine derivatives [7], doxorubicin and cisplatin [8]. Such
combinations have shown synergistic effects on different
types of cancer cells in vitro.
Lovastatin, a 3-hydroxy-3-methlyglutaryl CoA (HMG
CoA) reductase inhibitor is a commonly used cholesterol-
lowering agent for prevention of atherosclerotic cardio-
vascular diseases [9, 10]. Lovastatin blocks the mevalonate
pathway and reduces the formation of the downstream
products, cholesterol, geranylgeranyl proteins, farnesylated
[11]. Recently both in vitro and in vitro studies have found
that lovastatin has antiproliferative, proapoptotic and anti-
invasive properties in a wide range of cancer cell types
[12]. Lovastatin is known to have an apoptotic effect on
tumor cells and its combination with chemotherapeutics
and cytokines often exert a synergistic effect against tumor
growth [13–15]. The mechanism that leads to lovastatin-
induced apoptosis is not yet clear but the main event is
thought to be associated with the alteration of mitochon-
drial stress, which releases cytochrome C, activates pro-
caspase cascade and ﬁnally leads to apoptotic cell death.
Escape from apoptotic regulation is one of the major
characteristics of cancer [16, 17], and many successful
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Unfortunately such agents may also severely affect normal
cells. Given the fact that both lovastatin and TRAIL are
non-chemotherapeutic agents and capable of inducing
apoptosis in different types of cancer cells, it is important
to determine whether the combination of these two agents
would produce synergistic effects that may be lighten for a
novel therapeutic application in gliomas.
We therefore hypothesized that the combination of
TRAIL and lovastatin, neither of which alone has noxious
effects on healthy cells, could generate a regime that was
effective in killing cancer cells but caused minimal insult
to normal healthy cells. In this study we report the effects
of TRAIL in combination with a non-chemotherapeutic
drug, lovastatin, on glioblastoma cells.
Materials and methods
Reagents
2-Methyl-1,2,3,7,8,8a-hexahdro-3,7-dimethyl-8-[2-(tetra-
hydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthale-
nyl ester butanoic acid (Lovastatin), DL-Mevalonic acid
lactone, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) were purchased from Sigma (St
Louis, MO). Lovastatin was dissolved in DMSO for stock
and adjusted to ﬁnal concentrations using complete med-
ium or serum free medium. Soluble Human TRAIL
(Apo2L) was afﬁnity puriﬁed from lysates of bacteria
transformed with pET plasmid containing TRAIL [18].
Cellular DNA fragmentation ELISA kit (Roche, Mann-
heim, Germany), RNeasy kit, DNA extraction kit (Qiagen,
Germany) and RT-PCR kit (Promega, Madison, WI) were
used. Three primary antibodies used were as follows: rabbit
polyclonal antibody to DR4 (Chemicon International,
1:1,000 dilution), rabbit polyclonal antibody to DR5 (Cell
Signaling Technology, 1:1,000 dilution), and rabbit poly-
clonal antibody to b-tubulin (Santa Cruz Biotechnology,
1:1,000 dilution). Goat anti-rabbit secondary antibody was
obtained from Santa Cruz Biotechnology.
Cell culture
Three human glioblastoma cell lines, A172, M059J, and
M059K were purchased from American Type Culture
Collection (Rockville, MD). The glioblastoma cells were
kept in Dulbecco’s modiﬁed Eagle’s medium (DMEM/
F12) (GIBCO BRL, Grand Island, NY) with or without
10% fetal bovine serum, 1% penicillin and streptomycin at
37 C under 5% CO2. Media were changed every 3 days.
Measurement of cell viability
We measured cell viability using the MTT assay. MTT is a
water-soluble tetrazolium salt that is metabolized by viable
cells to a colored, water-insoluble formazan salt. Thus the
salt allows cell viability measurements. In short, 1 · 10
4
cells were cultured in the serum free DMEM/F12 medium
in the presence of lovastatin with or without TRAIL in a 96
well microtiter plate for designated time periods. The
medium was aspirated and 100 ll MTT (0.5 mg/ml in
PBS) were added to each well and the cells incubated for
3 h. After MTT medium was aspirated, the cells were
solubilized in 200 ll DMSO. The optical density of each
sample at 570 nm (reference 630 nm) was measured using
a microplate reader. The optical density of the media was
proportional to the degree of viable cells.
Cell cycle analysis
Propidium iodide (PI) staining and ﬂow cytometry were
used to determine the stage of the cell cycle. Cells were
treated with 20 lM lovastatin for 48 h at 37 C and the
control cells were treated with normal medium (DMSO)
or serum free medium (DMSO). 2 · 10
6 treated cells
were washed with 5 ml PBS and then were trypsinized at
37 C for 5–10 min. Cells were spun down and washed
with 5 ml PBS. Finally cells were resuspended in 500 ll
PBS and ﬁxed with 4.5 ml 70% Ethanol with gentle
vortexing. Cells were allowed to sit in –20 C for over-
night. Fixed cells were spun down and washed with 5 ml
PBS, and then cells were resuspended in 500 llP I( 2lg/
ml)/Triton X-100 (0.1% v/v) staining solution with RNase
A (200 lg/ml) in dark and analyzed by a ﬂow cytometer.
The staining solution was purchased from Chemicon
(Temecula, CA).
Apoptosis assay
Apoptotic cells were determined by two methods,
Annexin-V and PI stained cells by ﬂow cytometry and
DNA fragmentation assay. During apoptosis, translocation
of phosphatidylserine from inner membrane to outer
membrane is a common phenomenon. Cells were stained
with Annexin V for analysis of phosphoserine inversion,
which was considered to be a sensitive marker of apoptosis.
Using an Annexin V-FITC apoptosis detection kit
(Molecular Probe Inc, Eugene, OR), the levels of binding
of Annexin V and staining with PI were measured for the
detection of early and late apoptosis respectively. All of the
procedures were preformed under manufacturer’s guide-
lines. Cells were treated with lovastatin or/and TRAIL for
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12348 h and then stained with Annexin-V and PI. Viable cells
were recognized as negative for both Annexin-V and PI;
early apoptotic events were positive for Annexin-V but
negative for PI staining. Late apoptotic events were posi-
tive to both Annexin V and PI. Necrotic cells were positive
for PI staining only.
DNA fragmentation determination, was carried out with
the ELISA assay kit. After cells (1 · 10
4) were treated with
lovastatin and/or TRAIL for 48 h, DNA fragmentation was
detected using 96 wells microplate reader.
RT-PCR
Total RNA was isolated using Qiagen RNeasy extraction
kit and performed according to the manufacturer’s proto-
col. Total RNA (5 lg) was reversely transcribed using
Promega RT-PCR kit and thermal program was set at 42 C
for 15 min and 95 C for 5 min. PCR reaction was per-
formed using the following primers, which have previously
been tested successfully: TRAIL-R1, 50-CTG AGC AAC
GCA GAC TCG CTG TCC AC-30 and 50-TCC AAG GAC
ACG GCA GAG CCT GTG CCA T-30; TRAIL-R2, 50-
GCC TCA TGG ACA ATG AGA TAA AGG TGG CT-30
and 50-CCA AAT CTC AAA GTA CGC ACA AAC GG-
30; TRAIL-R3, 50-GAA GAA TTT GGT GCC AAT GCC
ACT G-30 and 50-CTC TTG GAC TTG GCT GGG AGA
TGT G-30; TRAIL-R4, 50-CTT TTC CGG CGG CGT TCA
TGT CCT TC-30 and 50-GTT TCT TCC AGG CTG CTT
CCC TTT GTA G-30. The thermal program was set up as
one cycle at 94 C for 5 min, 30 cycles at 94 C for 1 min,
55 C for 1 min, 72 C for 2 min, and one cycle at 72 C for
5 min. PCR products were resolved and visualized on a 2%
agarose gel stained with ethidium bromide.
Western blot analysis
Western blot was performed according to previous
description [19, 20]. Brieﬂy, after 2 · 10
6 cells were
treated for 48 h, total protein was isolated and reacted with
the relevant antibodies. The probed proteins were visual-
ized using the enhanced chemiluminescence Western
blotting detection system (ECL Western Blotting Detec-
tion, Amersham Biosciences).
Statistics
The statistical signiﬁcance was analyzed using one-way
ANOVA analysis and Student’s t-test. All statistical work
was carried out using the SPSS software for Windows
(Release 11.0.1, Chicago, IL). Differences were considered
to be signiﬁcant when P\0.05.
Results
Cell viability measured by MTT assay
We ﬁrst examined the anti-proliferation effect of TRAIL
on three glioblastoma cell lines. M059K and M059J glio-
blastoma cells were resistant to TRAIL-induced cell death
and remained 100% cell viable following treatment in both
normal and serum free conditions (Fig. 1a, b). Only A172
showed minor cell death after TRAIL treatment (22%,
Fig. 1a).
Synergistic effects by TRAIL and lovastatin were then
examined. A172, M059J, and M059K glioblastoma cells
were incubated in 1, 5, 20, and 40 lM lovastatin alone or
together with 500 ng/ml TRAIL for 48 h. In A172 glio-
blastoma cells, 5, 20, and 40 lM lovastatin with 500 ng/
ml TRAIL promoted signiﬁcant cell death when com-
pared with lovastatin control (Fig. 2a). 5, 20 and 40 lM
lovastatin alone induced 50%, 60% and 76% of cell death
respectively, however in the presence of 500 ng/ml
TRAIL, lovastatin induced 78%, 94%, and 92% of cell
death respectively. 1, 5, 20, and 40 lM lovastatin with
500 ng/ml TRAIL also synergistically promoted cell
death in M059J and M059K. In M059J cells, 1, 5, 20 and
Normal Medium
0
20
40
60
80
100
120
140
M059K
%
 
o
f
 
v
i
a
b
i
l
i
t
y
 
c
e
l
l
s
%
 
o
f
 
v
i
a
b
i
l
i
t
y
 
c
e
l
l
s
Control
500 ng/ml TRAIL
1000 ng/ml TRAIL
Serum Free medium
0
20
40
60
80
100
120
140
Control
500 ng/ml TRAIL
1000 ng/ml TRAIL
A172 M059J
M059K A172 M059J
A
B
Fig. 1 Anti-proliferation effects on glioblastoma cell lines A172,
M059K, and M059J. MTT assays were preformed after 48 h
incubation time treated with 0, 500, 1,000 ng/ml TRAIL in normal
medium (a) or serum free medium (b). A172 subjected to minor
TRAIL-induced cell death while M059J and M059K cells were
resistant to TRAIL. Same trend of data were obtained in both normal
medium and serum free condition. Experiment set were repeated at
least three times with triplicate wells for each condition (mean ± SD)
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12340 lM lovastatin alone caused 40%, 55%, 40% and 60%
cell death whereas in the presence of 500 ng/ml TRAIL,
lovastatin induced 83%, 94%, 95% and 95% cell death
respectively (Fig. 2b). There were 26%, 51%, 58%, and
71% cell death induced by 1, 5, 20, and 40 lM lovastatin
alone in M059K, in the presence of 500 ng/ml TRAIL,
lovastatin at all concentration tested caused about 98% of
cell death (Fig. 2c). Collectively the combination of
TRAIL and lovastatin was much more effective than
lovastatin alone in the induction of cell death in all three
glioblastoma cells tested and the result indicated that
there was a synergistic effect when TRAIL and lovastatin
were used together.
Cell cycle determination by PI staining
Propidium iodide staining and ﬂow cytometry were used to
determine the degree of cell synchronization by 20 lM
lovastatin. Cells were incubated with normal serum med-
ium, serum free medium and 20 lM lovastatin with normal
serum medium for 48 h. PI-stained cells were analyzed
using ﬂow cytometry to quantify cells in certain cell cycle
stages. A signiﬁcant increase in cell population at G0/G1
phase was observed when the cells were treated with
20 lM lovastatin indicating that lovastatin was able to
arrest the cells at G0/G1 stage. G0/G1 cell population was
also increased by serum free medium conditions (positive
control) and the increase reached a signiﬁcant level except
in M059J cells (Fig. 3).
Apoptosis is the major mode of cell death
In order to determine the mode of cell death induced by
lovastatin and TRAIL, Annexin V and PI staining was
employed for this purpose. Cells were incubated with 5 or
20 lM of lovastatin in the presence or absence of 500 ng/
ml TRAIL for 48 h. The percentage of cell death of
glioblastoma cells treated with both lovastatin and TRAIL
was signiﬁcantly higher than that with either agent alone
(Fig. 4a, b and c). A172 glioblastoma cells were vulner-
able to TRAIL induced apoptosis (Fig. 4a) but
signiﬁcantly more apoptotic cells were observed follow-
ing treatment with both TRAIL and lovastatin
(P\0.005) (Fig. 4a). TRAIL was able to induce apop-
tosis in 50% of A172 glioblastoma cells. However,
TRAIL in combination with 5 and 20 lM could induce
apoptosis in approximately 67% and 74% cells respec-
tively, indicating a synergistic effect occurred. Similarly,
a signiﬁcant synergistic effect was also observed in
M059K and M059J cells (P\0.005) (Fig. 4b, c), with up
to nearly a 10-fold increase in apoptotic cells. 5 lM
lovastatin only induced apoptosis in 5.3% and 2.3%
M059J and M059K respectively, which were not different
from the control (without any treatment). 5 lM lovastatin
plus 500 ng/ml TRAIL dramatically increased apoptotic
cells to 47.8% and 61.4% in M059J and M059K respec-
tively. M059J cells, which lack of DNA-dependent
protein kinase expression [21], were less vulnerable to the
two agents, implying that DNA-dependent protein kinase
may play a role in apoptosis induced by TRAIL and
lovastatin.
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Fig. 2 Synergistic anti-proliferation effects on glioblastoma cell lines
A172, M059J, and M059K. Glioblastoma cells were treated with 0, 5,
20 and 40 lM lovastatin alone or 0 lM lovastatin plus 500 ng/ml
TRAIL, 5 lM lovastatin plus 500 ng/ml TRAIL, 20 lM lovastatin
plus 500 ng/ml TRAIL and 40 lM lovastatin plus 500 ng/ml TRAIL
for 48 h. Percentage of viable glioblastoma cells showed synergistic
anti-proliferation effects by combined the two agents. In A172
glioblastoma cells (a), 500 ng/ml TRAIL with 5, 20 and 40 lM
lovastatin induced cell death signiﬁcantly when compared with
lovastatin only groups. In M059J (b) and M059K (c), 500 ng/ml
TRAIL with 1, 5, 20 and 40 lM lovastatin induced cell death
signiﬁcantly when compared with lovastatin only groups. ANOVA
were used for statistics analysis and *P\0.05, **P\0.01. Exper-
imental set were repeated for at least three times with triplicate wells
for each condition (mean ± SD)
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DNA fragmentation is one of the hallmarks when cells
undergo apoptosis. We performed ELISA assay to conﬁrm
DNA fragmentation was induced in the cells treated with
both lovastatin and TRAIL. A synergistic effect on DNA
fragmentation by both agents was demonstrated in all three
cell lines tested (Fig. 5a, b and c). The level of DNA
fragmentation was increased in treated A172 glioblastoma
cells, but it was only statistically signiﬁcant in the cells
treated with TRAIL plus 20 lM lovastatin. In M059J and
M059K cells, however, there was a dramatic elevation of
DNA fragmentation in a dose-dependent manner when
both of the agents were applied. This observation supports
the argument that the cell death induced by the two agents
was apoptotic and that both agents were able to function in
a synergistic manner.
The expression of TRAIL receptors in glioblastoma
cells
Resistance to cell death induced by TRAIL may be adapted
by an altered level of TRAIL receptors. TRAIL-R3 (DcR1)
and TRAIL-R4 (DcR2) are known to attenuate TRAIL-
induced apoptosis whereas TRAIL-R1 (DR4) and TRAIL-
R2 (DR5) promote TRAIL-induced apoptosis [5]. The
effect of lovastatin treatment on the TRAIL receptors was
not determined. RT-PCR was performed to investigate the
expression proﬁles on three glioblastoma cell lines tested.
Cells were treated with normal serum medium, serum free
medium, serum medium with 5 or 20 lM lovastatin for
48 h. TRAIL-R3 and R4 were not detected in all conditions
and cell types tested. TRAIL-R1 was only detected on
M059J cells with serum free medium or lovastatin (Fig. 6
a). TRAIL-R2 was expressed on all cell types of cells with
or without lovastatin and its level was not signiﬁcantly
different between lovastatin-treated cells and the controls.
Therefore, the expression of TRAIL-R2 did not contribute
to the lovastatin-induced cell death in glioblastoma cells
tested.
After we tested the mRNA expression of TRAIL
receptors on glioblastoma cells, the further investigation
was performed to determine the active protein expression
of TRAIL-R1 and matured TRAIL-R2 by Western blot.
The result showed that the protein expression proﬁles of
TRAIL-R1 and TRAIL-R2 were found in three glioblas-
toma cells with or without lovastatin, suggesting the
protein of these two receptors was underwent post-trans-
lational modiﬁcations. The signiﬁcantly differences were
only found on the TRAIL-R1 expression of M059K cells
with 20 lM lovastatin (P = 0.05) and the expression of
TRAIL-R2 in A172 cells with lovastatin (P\0.01)
(Fig. 7).
Discussion
Malignant glioblastoma is one of the major causes of brain
tumors morbidity. Aggressive inﬁltration in the CNS ulti-
mately leads to death in nearly all cases [2]. Malignant
glioblastoma carries with aberrant biological and bio-
chemical properties including several activating mutations
that can lead to chemotherapeutics resistance [22]. Tar-
geting apoptotic signaling machinery is thought to be a
promising alternative for glioblastoma treatment [23]. The
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123preliminary data presented in this report indicate that lov-
astatin, a blood cholesterol lowering medicine, sensitizes
glioblastoma cells to TRAIL-mediated apoptosis. Earlier
reports show statin-induced cell death through a mito-
chondrial-mediate pathway (intrinsic pathway) that is
closely related to the Bcl-2 family protein Bid and activa-
tion of caspase 8, 9 and 3 [24–27]. However, the mechanism
for statin activation of caspase 8 remains unknown because
caspase 8 is normally activated by receptor-mediated sig-
nals, such as Fas ligand and TRAIL [5].
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Fig. 4 The synergistic
apoptotic effects were
quantiﬁed by ﬂow cytometry
using Annexin V and PI
staining. Glioblastoma cells
were treated with DMSO
(Control), 5 lM lovastatin,
20 lM lovastatin, 500 ng/ml
TRAIL, 5 lM lovastatin plus
500 ng/ml TRAIL and 20 lM
lovastatin plus 500 ng/ml
TRAIL for 48 h. Then cells
were stained with Annexin V
and PI to determine percentage
of apoptotic cell death using
ﬂow cytometry. Synergistic
apoptotic effects were observed
in three glioblastoma cell lines
A172 (a), M059J (b) and
M059K (c), reached signiﬁcant
level. The portion of apoptotic
cell death was indicated in low-
right quarter of the ﬂow-
cytometry scatter plot and the
trend of apoptotic cells between
groups. ANOVA were used for
statistics analysis and
*P\0.05, **P\0.01
(compared to control group),
+P\0.05,
++P\0.01
(compared to TRAIL only
group). Experimental set were
repeated for at least three times
(mean ± SD)
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123Lovastatin has been found to enhance TRAIL-induced
cytotoxicity in a synergistic manner in glioblastoma cells.
We demonstrated a synergistic effect produced by the
combination of lovastatin and TRAIL on glioblastoma
cells. Lovastatin was found to sensitize the cells to cell
death induced by TRAIL. The mode of cell death induced
by both agents in combination was apoptosis, as demon-
strated by two different methods, Annexin V and PI
staining and DNA fragmentation assay. We also demon-
strated that two of the glioblastoma cell lines tested were
resistant to TRAIL induced apoptosis. From this we
inferred that lovastatin not only sensitized these glioblas-
toma cells through its effects on the TRAIL receptor
pathway but also triggered an unknown mechanism: Lov-
astatin served as a cytostatic agent and turned on an
unknown mechanism to support TRAIL-induced apoptosis
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Fig. 5 DNA fragmentation was
detected in combination of
lovastatin and TRAIL. Same
treatment in apoptotic cell
staining was preformed for
DNA fragmentation ELISA
detection. Signiﬁcant level of
DNA fragmentation was
detected in all glioblastoma
cells when combined with
lovastatin and TRAIL. ANOVA
were used for statistics analysis
and *P\0.05, **P\0.01
(compared to control group),
+P\0.05,
++P\0.01
(compared to TRAIL only
group). Experimental set were
repeated for at least three times
(mean ± SD)
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123in these glioblastoma cells. It has been shown that colon
and lung tumor cells arrested in G0–G1 stages are vulner-
able to TRAIL-induced cell death [28]. However, our G0–
G1 arrested glioblastoma cell lines remained resistant to
TRAIL-induced cell death in the serum free control. Our
ﬁnding suggests that a combination of TRAIL and lova-
statin together may form a new treatment for glioblastoma
multiforme.
The mechanism by which lovastatin sensitizes glio-
blastoma cells to TRAIL induced-apoptosis remains
unknown. In human glioblastoma, lovastatin has been
shown to induce or to enhance apoptosis by altering a
number of apoptotic molecules. For example, it can induce
apoptosis or downregulate cell proliferation by targeting
Ras in primary cultured human glioblastoma cells [29] and
increase pro-apoptotic Bim in U87 and U251 glioblastoma
cells [30]. Lovastatin has also been shown to downregulate
RhoA and increase iNOS in T98G and A172 glioblastoma
cells [31]. Additionally, Lovastatin may induce apoptosis
by increasing p21 and the apoptosis induced can be pre-
vented by the overexpression of Bcl-2 [32], suggesting a
mitochondrial-related apoptosis. It is noted that this study
by Schmidt et al. fails to document that lovastatin can
enhance death receptor (CD95)-mediated apoptosis in
glioblastoma cells LN-18, LN-229, LN-308 and T98G
[32]. The result from our study indicate that lovastatin in
combination with TRAIL can synergistically induce
apoptosis in A172, M059K and M059J glioblastoma cells.
The apoptosis induced is associated with G0–G1 arrest but
not with pro-apoptotic Bid (data not shown). It is well
known that TRAIL-induced apoptosis takes place via a
death receptor-mediated pathway [5, 33].
Our study showed that TRAIL-R1 mRNA expressed in
M059J but was hardly detected in the other two cell lines.
However, TRAIL-R1 protein was detectable in all three
cell lines, suggesting that the TRAIL-R1 was modiﬁed by a
post-translational mechanism in the cells tested. The level
of TRAIL-R1 protein was higher in M059K cells treated
with 20 lM of lovastatin. However, such an elevation of
TRAIL-R1 is unlikely to be responsible for apoptosis
induced by lovastatin because the apoptotic rate between
M059K was not different from the other cell lines. TRAIL-
R2 can be detected at both protein and RNA levels. The
level of TRAIL-2 mRNA was not different in the cells
treated with lovastatin but its protein level was much
higher in A178 cells treated with either 5 or 10 mM lov-
astatin, the result of which indicated that TRAIL-R2 was
modiﬁed by a post-translational mechanism in A172 cells.
It is noted that the base level of TRAIL-2 in A172 cells
does not differ from other two cell lines tested. Therefore,
it is unlikely that TRAIL-2 could count for the relatively
higher sensitivity of A172 cells to TRAIL stimulation than
the other two cell lines. All three cell lines underwent a
similar level of cell death when they were treated by lov-
astatin. Therefore, the contribution of lovastatin-induced
TRAIL-2 protein to the cell death in A172 cells seems to be
minimal. Such results appear to be in line with a study
using mevastatin, a similar HMG-CoA reductase inhibitor.
Mevastatin can signiﬁcantly induce apoptosis of myeloma
cells in a pathway independent of death receptors including
Fig. 6 The expression of
TRAIL receptor mRNA in
glioblastoma cells. The cells
were treated with normal serum
medium, serum free medium, 5
and 20 lM lovastatin with
normal serum medium. At the
end of the treatment, RNA was
isolated for the detection of
TRAIL-R1 (DR4) (a) and
TRAIL-R2 (DR5) (b) by RT-
PCR
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123TRAIL-R2 [34]. Nevertheless, further quantitative tests are
needed in glioblastoma cells to verify the result obtained.
Apoptosis induced by lovastatin is generally considered
to be via the mitochondrial-mediated pathway [30; 32]. It is
possible for both pathways to talk to each other to amplify
apoptotic signals and this is indeed a case for TRAIL, since
TRAIL is capable of inducing either mitochondrial-inde-
pendent or -dependent apoptotic pathways in some types of
cells [17, 33]. The Bid is a molecule functions as a bridge
that links death receptor- and mitochondrial-mediated
pathways. Therefore, without involvement of Bid, apop-
tosis induced by TRAIL and lovastatin in combination in
the present study seem to be separately mediated by these
two pathways. However, considering the fact that two out
of three glioblastoma cells tested are insensitive to TRAIL
treatment but they become responsive in the presence of
lovastatin, it can be hypothesized that lovastatin treatment
may remove an unknown inhibitory factor(s) that over-
comes the TRAIL-mediated pathway or that lovastatin may
‘‘wake up’’ an activator(s) that normally remains in a
resting condition. One of inhibitory factors known to
involve TRAIL-mediated pathways is its decoys, TRAIL-
R3 and TRAIL-R4 [5, 33]. However, it can be seem from
our study that this inhibitory factor(s), if any, should not be
the decoys TRAIL-R3 and TRAIL-R4 since both are not
detectable in the cells tested. One possible explanation for
this synergistic effect is the activation of caspase 8, an
initiator caspase in death receptor-mediated pathways.
Lovastatin has been shown to enhance caspase 8 activity
[35]. It is possible that caspase-8 is the activator factors
waken up by lovastatin. Whatever it is, the mechanism
accounting for the synergistic effect of TRAIL and
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Fig. 7 The expression of
TRAIL-R1 (DR4) and TRAIL-
R2 (DR5) proteins in
glioblastoma cells. The cells
were treated with normal serum
medium, serum free medium, 5
and 20 lM lovastatin with
normal serum medium for 48 h.
At the end of the treatment,
proteins were isolated for the
detection of TRAIL-R1 (a, b)
and TRAIL-R2 (c, d)b y
Western blot. Representative
Western blots were shown (a,
c). The target bands were
scanned and normalized to b-
tubulin. The index of densities
was calculated (b, d).
*P = 0.05, **P\0.01
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123lovastatin against glioblastoma cells in the present study is
complicated and remains to be uncovered.
Mevalonate is a critical component of a complex bio-
chemical pathway and its products are vital for a variety of
important cellular functions including cell signaling, pro-
tein synthesis, and cell cycle regulation [11]. Little is
known about the molecular events leading to apoptosis of
cancer cells due to lovastatin exposure. It is likely that
apoptosis is abrogated by mevalonate and GGPP and is
partially reversed by FPP [12].
Our results also reinforced the conclusion of our previ-
ous study, that DNA-dependent protein kinase (DNA-PK)
plays an important role in cell apoptosis. M059J cells that
lack of DNA-PK activity are resistant not only to total cell
death but also apoptosis [19, 20]. Experts disagree over the
functions of DNA-PK in cell regulation. DNA-PK has been
reported to promote cell death by interacting with telo-
meres, whereas other reports suggest that DNA-PK protects
cells from cell death via caspase-independent or p53
independent pathways. The reason for this paradoxical
ﬁnding remains unknown.
This study demonstrated a synergistic interaction
between lovastatin and TRAIL, but the mechanisms of
action by which lovastatin sensitized glioblastoma cells
remains unknown. Our results are in agreement with the
concept of combined cancer therapeutic action via both
intrinsic and extrinsic apoptotic cell death pathways. This
combination of non-chemotherapeutic agents, TRAIL and
lovastatin, may offer a potential regime for glioblastoma
treatment.
Acknowledgements We thank Mr. Billy C. S. Leung and Miss Suk-
Ying Chun for their technical assistance in the ﬂuorescence-activated
cell sorter analysis and cell cultures.
References
1. Grossman SA, Batara JF (2004) Current management of glio-
blastoma multiforme. Semin Oncol 31:635–644
2. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123
3. Reardon DA, Wen PY (2006) Therapeutic advances in the
treatment of glioblastoma: rationale and potential role of targeted
agents. Oncologist 11:152–164
4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl
JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al (1995)
Identiﬁcation and characterization of a new member of the TNF
family that induces apoptosis. Immunity 3:673–682
5. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and
modulation. Science 281:1305–1308
6. Kimberley FC, Screaton GR (2004) Following a TRAIL: update
on a ligand and its ﬁve receptors. Cell Res 14:359–372
7. Kato S, Shirato K, Imaizumi K, Toyota H, Mizuguchi J, Odawara
M, Che XF, Akiyama S, Abe A, Tomoda A (2006) Anticancer
effects of phenoxazine derivatives combined with tumor necrosis
factor-related apoptosis-inducing ligand on pancreatic cancer cell
lines, KLM-1 and MIA-PaCa-2. Oncol Rep 15:843–848
8. Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Bi-
nazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L,
Vitale M (2006) Anticancer agents sensitize osteosarcoma cells to
TNF-related apoptosis-inducing ligand downmodulating IAP
family proteins. Int J Oncol 28:127–133
9. Grundy SM (1988) HMG-CoA reductase inhibitors for treatment
of hypercholesterolemia. N Engl J Med 319:24–33
10. Ness GC, Zhao Z, Lopez D (1996) Inhibitors of cholesterol
biosynthesis increase hepatic low-density lipoprotein receptor
protein degradation. Arch Biochem Biophys 325:242–248
11. Goldstein JL, Brown MS (1990) Regulation of the mevalonate
pathway. Nature 343:425–430
12. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer
agents. Clin Cancer Res 9:10–19
13. Holstein SA, Hohl RJ (2001) Synergistic interaction of lovastatin
and paclitaxel in human cancer cells. Mol Cancer Ther 1:141–149
14. Werner M, Sacher J, Hohenegger M (2004) Mutual ampliﬁcation
of apoptosis by statin-induced mitochondrial stress and doxoru-
bicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol
143:715–724
15. Knapp AC, Huang J, Starling G, Kiener PA (2000) Inhibitors of
HMG-CoA reductase sensitize human smooth muscle cells to
Fas-ligand and cytokine-induced cell death. Atherosclerosis
152:217–227
16. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell
100:57–70
17. Reed JC (2000) Mechanisms of apoptosis. Am J Pathol
157:1415–1430
18. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M,
Chenevert TL, Ross BD, Rehemtulla A (2000) Combined effect
of tumor necrosis factor-related apoptosis-inducing ligand and
ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U
S A 97:1754–1759
19. Chen GG, Sin FL, Leung BC, Ng HK, Poon WS (2005) Glio-
blastoma cells deﬁcient in DNA-dependent protein kinase are
resistant to cell death. J Cell Physiol 203:127–132
20. Chen GG, Sin FL, Leung BC, Ng HK, Poon WS (2005) Differ-
ential role of hydrogen peroxide and staurosporine in induction of
cell death in glioblastoma cells lacking DNA-dependent protein
kinase. Apoptosis 10:185–192
21. Allalunis-Turner MJ, Barron GM, Day RS III, Dobler KD, Mir-
zayans R (1993) Isolation of two cell lines from a human
malignant glioma specimen differing in sensitivity to radiation
and chemotherapeutic drugs. Radiat Res 134:349–354
22. Kelley TW, Tubbs RR, Prayson RA (2005) Molecular diagnostic
techniques for the clinical evaluation of gliomas. Diagn Mol
Pathol 14:1–8
23. Rich JN, Bigner DD (2004) Development of novel targeted
therapies in the treatment of malignant glioma. Nat Rev Drug
Discov 3:430–446
24. Cafforio P, Dammacco F, Gernone A, Silvestris F (2005) Statins
activate the mitochondrial pathway of apoptosis in human lym-
phoblasts and myeloma cells. Carcinogenesis 26:883–891
25. Shibata MA, Ito Y, Morimoto J, Otsuki Y (2004) Lovastatin
inhibits tumor growth and lung metastasis in mouse mammary
carcinoma model: a p53-independent mitochondrial-mediated
apoptotic mechanism. Carcinogenesis 25:1887–1898
26. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner
M (2003) Simvastatin induces apoptosis of B-CLL cells by
activation of mitochondrial caspase 9. Exp Hematol 31:779–783
27. Janosi J, Sebestyen A, Bocsi J, Barna G, Nagy K, Valyi-Nagy I,
Kopper L (2004) Mevastatin induced apoptosis in U266 human
myeloma cell line. Magy Onkol 48:333–337
28. Jin Z, Dicker DT, El Deiry WS (2002) Enhanced sensitivity of G1
arrested human cancer cells suggests a novel therapeutic strategy
282 J Neurooncol (2008) 86:273–283
123using a combination of simvastatin and TRAIL. Cell Cycle 1:82–
89
29. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K,
Tonn JC (2000) Inhibition of Ras farnesylation by lovastatin
leads to downregulation of proliferation and migration in primary
cultured human glioblastoma cells. Anticancer Res 20:2761–2771
30. Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM (2004)
Lovastatin-induced up-regulation of the BH3-only protein, Bim,
and cell death in glioblastoma cells. J Neurochem 89:168–178
31. Rattan R, Giri S, Singh AK, Singh I (2003) Rho A negatively
regulates cytokine-mediated inducible nitric oxide synthase
expression in brain-derived transformed cell lines: negative reg-
ulation of IKKalpha. Free Radic Biol Med 35:1037–1050
32. Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M (2001)
Lovastatin and phenylacetate induce apoptosis, but not differen-
tiation, in human malignant glioma cells. Acta Neuropathol
101:217–224
33. Bouralexis S, Findlay DM, Evdokiou A (2005) Death to the bad
guys: targeting cancer via Apo2L/TRAIL. Apoptosis 10:35–51
34. Janosi J, Sebestyen A, Bocsi J, Barna G, Nagy K, Valyi-Nagy I,
Kopper L (2004) Mevastatin-induced apoptosis and growth sup-
pression in U266 myeloma cells. Anticancer Res 24:1817–1822
35. Knight MJ, Riffkin CD, Ekert PG, Ashley DM, Hawkins CJ
(2004) Caspase-8 levels affect necessity for mitochondrial
ampliﬁcation in death ligand-induced glioma cell apoptosis. Mol
Carcinog 39:173–182
J Neurooncol (2008) 86:273–283 283
123